These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 17030663)
1. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Rosenmann H; Grigoriadis N; Karussis D; Boimel M; Touloumi O; Ovadia H; Abramsky O Arch Neurol; 2006 Oct; 63(10):1459-67. PubMed ID: 17030663 [TBL] [Abstract][Full Text] [Related]
2. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Boimel M; Grigoriadis N; Lourbopoulos A; Haber E; Abramsky O; Rosenmann H Exp Neurol; 2010 Aug; 224(2):472-85. PubMed ID: 20546729 [TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
6. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models. Zhang Q; Zhang X; Sun A Acta Neuropathol; 2009 Jun; 117(6):687-97. PubMed ID: 19190923 [TBL] [Abstract][Full Text] [Related]
7. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695 [TBL] [Abstract][Full Text] [Related]
8. [Animal models of tauopathies]. Higuchi M Rinsho Shinkeigaku; 2006 Nov; 46(11):928-30. PubMed ID: 17432223 [TBL] [Abstract][Full Text] [Related]
9. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Rosenmann H; Meiner Z; Geylis V; Abramsky O; Steinitz M Neurosci Lett; 2006 Dec; 410(2):90-3. PubMed ID: 17095156 [TBL] [Abstract][Full Text] [Related]
10. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration. Walton JR J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457 [TBL] [Abstract][Full Text] [Related]
11. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Kayed R; Jackson GR Curr Opin Immunol; 2009 Jun; 21(3):359-63. PubMed ID: 19482462 [TBL] [Abstract][Full Text] [Related]
12. Neurofibrillary tangles may interfere with Smad 2/3 signaling in neurons. Chalmers KA; Love S J Neuropathol Exp Neurol; 2007 Feb; 66(2):158-67. PubMed ID: 17279001 [TBL] [Abstract][Full Text] [Related]
13. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. Taniguchi T; Doe N; Matsuyama S; Kitamura Y; Mori H; Saito N; Tanaka C FEBS Lett; 2005 Oct; 579(25):5704-12. PubMed ID: 16219306 [TBL] [Abstract][Full Text] [Related]
14. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130 [TBL] [Abstract][Full Text] [Related]
15. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau. Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643 [TBL] [Abstract][Full Text] [Related]
16. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. Boimel M; Grigoriadis N; Lourbopoulos A; Touloumi O; Rosenmann D; Abramsky O; Rosenmann H J Neuropathol Exp Neurol; 2009 Mar; 68(3):314-25. PubMed ID: 19225406 [TBL] [Abstract][Full Text] [Related]
17. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation. Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756 [TBL] [Abstract][Full Text] [Related]
18. Substrate-specific reduction of PP2A activity exaggerates tau pathology. Deters N; Ittner LM; Götz J Biochem Biophys Res Commun; 2009 Feb; 379(2):400-5. PubMed ID: 19126401 [TBL] [Abstract][Full Text] [Related]
19. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition. Flood DG; Lin YG; Lang DM; Trusko SP; Hirsch JD; Savage MJ; Scott RW; Howland DS Neurobiol Aging; 2009 Jul; 30(7):1078-90. PubMed ID: 18053619 [TBL] [Abstract][Full Text] [Related]